GlassScriptPhysician profile
Fiona Dulbecco
NPI 1760574446
$2,690.68
in general payments reported to CMS, 2019-2025
10 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $188 · 2023: $256 · 2024: $1,571 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,374 · Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,374.35 |
| Food and Beverage | $748.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,374.35 | 2024 | Brilinta |
| Abbott Laboratories | $370.46 | 2019-2020 | |
| Baxter Healthcare | $196.87 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Heartflow, INC. | $169.17 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.98 | 2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.84 | 2023 | Lifevest |
| Novo Nordisk INC | $120.60 | 2023 | |
| Medtronic Vascular, INC. | $72.66 | 2019 | |
| Biotronik INC. | $12.75 | 2023 | Edora 8 Dr-T, Acticor 7 Vr-T Dx, Biomonitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Dulbecco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.